Safety/Proof of Concept Study of Oral QLT091001 in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations
A Phase 1b Study to Evaluate QLT091001 in Subjects (at least five years old) with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinyl Transferase (LRAT).
The purpose of this study is:
- to evaluate the safety of oral QLT091001
- to evaluate whether 7-day treatment with oral QLT091001 can improve visual function in subjects with LCA or RP due to RPE65 or LRAT mutations
- to evaluate duration of visual function improvement (if observed)
For more information, visit ClinicalTrials.gov.
Contact Information
QLT Medical Information
1-877-764-3131
medaff@qltinc.com
|
